An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

Ki vehet részt

• Participants with CRSwNP who completed the 52-weeks intervention period in a previous itepekimab CRSwNP Phase 3 clinical study (ie, EFC18418 or EFC18419) and for which an EOT visit occurred no later than 5 days before the enrollment visit of this study
• A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:; Is not a women of childbearing potential (WOCBP), OR; Is a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 20 weeks after the last dose of study intervention

Ki nem vehet részt

• Diagnosis of a malignancy during parent study, except a squamous or basal cell carcinoma of the skin
• Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an immunocompromised status
• Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study
• Participants are excluded from the study if any of the following criteria apply:
• Any other situation that led to a permanent premature IMP discontinuation in parent trials; The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial